Conduit Pharma and Agility Life Partner for Autoimmune Drug Development

Conduit Pharmaceuticals Inc. announced that it has established a strategic services partnership with the formulation development CDMO Agility Life Sciences (“Agility”) to create new solid oral-dosage form products for its autoimmune pipeline intended for future clinical trials.

Conduit has created a range of unique, beneficial solid forms for all its autoimmune pipeline assets, each safeguarded by newly obtained composition-of-matter intellectual property (IP). Utilizing Agility’s vast formulation knowledge, Conduit anticipates that this partnership will aim to apply these unique forms to create improved oral dosage forms for every asset. These dosage forms, crafted with consideration for patient desires and specific disease requirements, aim to enable Conduit to optimize the market potential of every asset, supported by strong composition of matter intellectual property.

In alignment with its objective of obtaining Phase 2-ready assets, Conduit’s pipeline features multiple candidates that possess clinically evaluated oral formulations. This allows the Company to effectively proceed to Phase 2 trials utilizing current data packages. Simultaneously with the current autoimmune clinical trial initiatives, Conduit will collaborate with Agility to create improved proprietary oral dosage forms for each asset. This dual-track strategy aims to fortify market protection, boost market value, and improve the positioning of each asset for forthcoming licensing prospects.